Showing results (21-30 of 77) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|May 1, 2014
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?Ole Audun Werner Haabeth, Anders Aune Tveita, Marte Fauskanger, et al.
American Journal of Hematology|March 27, 2025
Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-AnalysisJoshua Richter, Ajay Nooka, Paula Rodríguez-Otero, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 28, 2025
Progression-Free and Overall Survival After KRd Consolidation in FDG PET/CT Positive Patients After ASCT: A Phase II Study (CONPET)Jakob Nordberg Nørgaard, Niels Abildgaard, Anna Lysén, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose AdjustmentAlbert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 30, 2022
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple MyelomaFredrik Schjesvold, Bruno Paiva, Vincent Ribrag, et al.
Leukemia|August 11, 2023
Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantationJakob Nordberg Nørgaard, Niels Abildgaard, Anna Lysén, et al.
Ejhaem|January 27, 2025
Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma-A Phase I Trial of Hydroxychloroquine, Carfilzomib, and DexamethasoneTobias S Slørdahl, Frida Bugge Askeland, Margrete Sofie Sætre Hanssen, et al.
Cell Reports Methods|April 14, 2023
Phenotypic deconvolution in heterogeneous cancer cell populations using drug-screening dataAlvaro Köhn-Luque, Even Moa Myklebust, Dagim Shiferaw Tadele, et al.
Annals of Hematology|August 9, 2022
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomesXavier Leleu, Thomas Martin, Katja Weisel, et al.
Frontiers in Oncology|December 16, 2022
What matters most to patients with multiple myeloma? A Pan-European patient preference studyRosanne Janssens, Tamika Lang, Ana Vallejo, et al.
Pageof 8